• TTP399 increased Time in Range, reduced hyperglycemia time, a bolus insulin dose that was lower and fewer hypoglycemic events.
   
• TTP399 could be placed for Phase 3 development to address Type 1 Diabetes.

vTv Therapeutics Inc., a biopharmaceutical company that discovers and develop small molecule drug, reportedly presented additional positive data at the 55^th Annual Meeting of the European Association for the Study of Diabetes from the company’s phase 2 Simplici-T1 study in patients suffering from type 1 diabetes (T1D).

During the banner session, Chief Scientific Officer of vTv Therapeutics, Dr. Carmen Valcarce presented new CGM (Continuous Glucose Monitor) as well as insulin dose information from subjects that had complete CGM profiles in part 1 of the completed Phase 2 study.

Key results that were presented include points like TTP399 treatment increasing the Time in Range; since the beginning to the end of the treatment by about 11% per day. It also helped in the reduction of the daily total mealtime dose of bolus insulin, which dropped by 23% in comparison with the 4% from placebo while it improved glycemic control significantly.

Patients present in this treatment group also witnessed lesser Level 1 & Level 2 hypoglycemic events compared to the patients placed in the placebo group.

CEO and President of vTv Therapeutics, Steve Holcombe stated that the new clinical data strengthens the favoring topline efficacy results that the company announced for this particular part of the study in June, wherein TTP399 helped reduce HbA1c levels by 0.7% compared to placebo.

Holcombe further added that the company believes if these results were confirmed in the bigger and ongoing part of the study, they would position TTP399 for the development in Phase 3 and aid in addressing the needs of patients with T1D.

About vTv Therapeutics:

vTv Therapeutics is a biopharma company that develops oral small molecule drug. The company owns a pipeline of clinical drug candidates that has treatment programs for Alzheimer’s disease, inflammatory disorders, and diabetes.

Source Credit- http://ir.vtvtherapeutics.com/news-releases/news-release-details/vtv-therapeutics-presents-additional-positive-data-phase-2